sputum cytology


Also found in: Dictionary, Thesaurus, Encyclopedia.

sputum cytology

a sputum test to determine the presence of a pulmonary system malignancy. It is used most frequently in patients who have an abnormal chest x-ray, productive cough, and nothing visible on bronchoscopy. A positive test indicates malignancy, but a negative test means only that, if a tumor exists, it is not shedding cells.

sputum cytology

The examination of cells obtained from mucus in the upper or lower respiratory tract to see if cancer cells are present. See: sputum specimen.
See also: cytology
References in periodicals archive ?
This technique may, therefore, be of value in those elderly patients in whom bronchoscopy is relatively contra-indicated and in whom previous ordinary sputum cytology was either negative or no sputum was obtainable.
The diagnosis of primary lung cancer with special reference to sputum cytology.
The bottom line is that morbidity and mortality are not reduced when we use chest x-rays, sputum cytology, or a combination of the 2 in screening for lung cancer.
Another trial involved male smokers who were randomized to undergo chest x-ray and sputum cytology either every 6 months or after 3 years.
4) Studies using decision analytic techniques attempting to identify the most cost-effective strategy for diagnosis have advocated the use of either multiple sputum cytology, positron emission tomography, TFNAB, or thoracotomy as the optimal first diagnostic test for patient workup, depending on the individual study.
Members of both of these comparison groups were recruited and paid by the laboratory to provide a broad database for the firm's sputum cytology research.
stated that MonoGen's technology, coupled with LungCheck(R)'s state-of-the-art assessment of sputum cytology, offers a unique opportunity to diagnose lung cancer.
Sputum cytology in suspected cases of carcinoma of lung (Sputum cytology a poor man's bronchoscopy
However, most studies of LDCT have been observational and, like the traditional screening methods of CXR and sputum cytology, LDCT has not been proven to alter mortality, which is key to the definition of an effective screening test.
There is no evidence that screening even high-risk patients with chest radiographs and/or sputum cytology reduces mortality due to lung cancer.
Data suggest that the Chiron assay may provide a screening method that is potentially more sensitive, less invasive and less costly than traditional methods including, sputum cytology, x-ray and bronchsoscopy.
Xillix believes that the combination of sputum cytology and Xillix LIFE-Lung will provide a significant improvement by identifying high risk patients through a low cost and widely available screening tool.